KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Raw Materials (2016 - 2024)

Historic Raw Materials for Nektar Therapeutics (NKTR) over the last 13 years, with Q2 2024 value amounting to $1.7 million.

  • Nektar Therapeutics' Raw Materials changed N/A to $1.7 million in Q2 2024 from the same period last year, while for Jun 2024 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2023, which is 2772.82% down from last year.
  • As of Q2 2024, Nektar Therapeutics' Raw Materials stood at $1.7 million.
  • In the past 5 years, Nektar Therapeutics' Raw Materials ranged from a high of $2.6 million in Q4 2022 and a low of $1.7 million during Q2 2024
  • In the last 3 years, Nektar Therapeutics' Raw Materials had a median value of $1.9 million in 2023 and averaged $2.0 million.
  • The largest annual percentage gain for Nektar Therapeutics' Raw Materials in the last 5 years was 2772.82% (2023), contrasted with its biggest fall of 2772.82% (2023).
  • Quarter analysis of 3 years shows Nektar Therapeutics' Raw Materials stood at $2.6 million in 2022, then fell by 27.73% to $1.9 million in 2023, then dropped by 7.63% to $1.7 million in 2024.
  • Its Raw Materials was $1.7 million in Q2 2024, compared to $1.9 million in Q1 2024 and $1.9 million in Q4 2023.